Novo Nordisk Raises 2026 Outlook as Wegovy Pill Offsets Injector Decline — But US Price Cuts Loom
Published on 11/04/2026 at 13:51 | Editorial boerse-global.de
Novo Nordisk gave investors something to cheer on Wednesday, lifting its full-year guidance for a second time after a stronger-than-expected third quarter. Whether that optimism holds up is a separate question — and a harder one.
The Danish drugmaker now expects adjusted sales and adjusted operating profit for 2026 to move between -2% and +2% at constant exchange rates, a marked improvement on the prior range of -6% to 0%. The revision marks the first time the upper end of the guidance has pointed to outright growth. It hardly amounts to a bold expansion call, though: Reuters reports the company anticipates international growth alongside a decline in the US. Shares rose 4.8% on the news.
A Beat With a Caveat
Adjusted sales for the third quarter came in at DKK 79.20bn, comfortably ahead of the DKK 73.22bn analyst consensus cited by Reuters. Adjusted operating profit reached DKK 31.72bn, also topping forecasts. The headline beat is real — but it is not a clean read on underlying demand.
Jefferies estimates that pricing and reimbursement effects worth roughly DKK 2bn flattered the sales surprise. Strip those out, and revenue would still have beaten expectations by about 5%, according to the brokerage. That adjusted view still points to a healthier business than anticipated, yet it tempers the scale of the surprise. The real test is growth without such support.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The gap between adjusted and reported earnings deserves attention too. Novo booked impairments of DKK 8.7bn, leaving reported operating profit at DKK 23.011bn — a decline of 9% at constant currencies. Adjustments sharpen the view of the ongoing business; they do not erase the economic weight of write-downs.
The Pill Takes Centre Stage
The bull case rests on the Wegovy pill. Quarterly sales hit DKK 5.39bn, up 53% on the prior quarter and ahead of the DKK 4.62bn consensus, according to Reuters. What matters most is whether that growth represents genuinely new demand rather than a shift within the Wegovy family. If it does, it would broaden the revenue base and reduce reliance on the injectable form.
Early US data offer a hint. RTÉ reports that US sales of injectable Wegovy fell 13% at constant currencies, while combined US Wegovy revenue rose 21%. Should that pattern persist, the pill could do more than merely offset a weaker injector business — it could signal a wider demand base. The caveat: additional prescriptions must generate sufficient revenue and profit contribution under altered pricing conditions.
The January 2027 Price Test
The sternest examination comes with US list prices. From 1 January 2027, Wegovy and Ozempic are each slated to cost USD 675 per month, per Reuters — a move Novo expects to weigh on cash flow next year. List prices are not the same as realised net revenue, so the change cannot be mapped directly onto a corresponding sales decline. Even so, its economic impact ranks among the central risks to the recovery.
For Wegovy, the planned list price reduction is around 50%; for Ozempic, roughly 35%. In the bear case, additional volume growth would not be enough to absorb the hit.
Competition and the Calendar Ahead
The competitive backdrop adds a separate layer of risk. On 28 October, Reuters reported comments from Eli Lilly on its investigational drug Retatrutide, which delivered better blood-sugar control than Ozempic and more than double the weight loss in a diabetes study. The findings could raise the bar for Novo's future competitiveness. The scope of the claim is limited — Retatrutide remains an investigational compound, and the trial comparison implies neither an accomplished market displacement nor a quantifiable revenue impact. Still, it is a serious counterpoint to the optimistic guidance thesis.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Novo also confirmed it is pressing on with its share buyback programme, reporting further weekly repurchases on Tuesday. The capital measure is a factor in its own right, but no substitute for evidence of operational strength.
CagriSema offers another potential avenue. Novo plans a US launch for early 2027, subject to approval — a possible additional growth driver, not a secured one. Scientific gatherings will provide the next opportunities to assess the pipeline: the company has announced twelve abstracts on semaglutide clinical and care data for the Liver Meeting in Denver from 5 to 9 November, with further contributions on CagriSema, Wegovy pill care data and STEP Young slated for ObesityWeek in Washington from 14 to 17 November. Announced presentations are not positive results — but they are the next chance to look beyond the near-term financial guidance.
For now, the quarter points to operational improvement. Whether it matures into a durable recovery will be decided by how much sales growth and cash flow survive the coming price reset.
Ad
Novo Nordisk Stock: New Analysis - 4 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
